- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 10.03. | NeuroPace's Seizure ID and New Indication Could Expand RNS Demand | 1 | Zacks | ||
| 04.03. | Why NeuroPace Stock Was Inching Higher on Wednesday | 1 | The Motley Fool | ||
| 04.03. | NeuroPace reiterates $98M-$100M 2026 revenue target while advancing AI and IGE pipeline | 1 | Seeking Alpha | ||
| 03.03. | NeuroPace Inc - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 03.03. | NeuroPace Inc - 10-K, Annual Report | 2 | SEC Filings | ||
| 03.03. | Earnings Summary: NeuroPace Q4 | 2 | Benzinga.com | ||
| 03.03. | NeuroPace Inc - 8-K, Current Report | 2 | SEC Filings | ||
| NEUROPACE Aktie jetzt für 0€ handeln | |||||
| 02.03. | Earnings Outlook For NeuroPace | 1 | Benzinga.com | ||
| 02.02. | NeuroPace stock price target raised to $20 from $19 at Leerink Partners | 3 | Investing.com | ||
| 27.01. | NeuroPace stock price target raised to $19 from $18 at H.C. Wainwright | 1 | Investing.com | ||
| 27.01. | H.C. Wainwright hebt Kursziel für NeuroPace auf 19 US-Dollar an | 1 | Investing.com Deutsch | ||
| 27.01. | Beyond The Numbers: 5 Analysts Discuss NeuroPace Stock | 1 | Benzinga.com | ||
| 14.01. | NeuroPace-Aktie steigt nach starkem Q4-Umsatz und bestätigter UBS-Kaufempfehlung | 4 | Investing.com Deutsch | ||
| 13.01. | NeuroPace reports 25% revenue growth for 2025, projects steady growth | 1 | Investing.com | ||
| 13.01. | NeuroPace meldet 25 % Umsatzwachstum für 2025 und prognostiziert stetiges Wachstum | 1 | Investing.com Deutsch | ||
| 13.01. | NeuroPace sees Q4 revenue of about $26.6M | 2 | Seeking Alpha | ||
| 17.12.25 | NeuroPace seeks FDA approval to expand RNS System for epilepsy treatment | 4 | Investing.com | ||
| 03.12.25 | BDMD: Baird Medical Appoints Mark Saxton as U.S. CEO; Taps Veteran from NeuroPace, Smith + Nephew, and Covidien to Lead Commercial Expansion | 420 | PR Newswire | NEW YORK, Dec. 3, 2025 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a market leader in minimally invasive... ► Artikel lesen | |
| 10.11.25 | Cantor Fitzgerald bestätigt "Overweight"-Rating für NeuroPace nach starken Quartalszahlen | 3 | Investing.com Deutsch | ||
| 10.11.25 | Cantor Fitzgerald reiterates Overweight rating on NeuroPace stock | 1 | Investing.com |
1 2 Weiter >>
28 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BRIGHTSPRING HEALTH SERVICES | 52,55 | +9,39 % | BrightSpring mischt einen Milliardenmarkt auf | Auf den ersten Blick ist das Geschäft von BrightSpring margenschwach und wenig attraktiv. Doch gerade das eröffnet enorme Chancen für Skalierung und Konsolidierung Den vollständigen Artikel lesen ... ► Artikel lesen | |
| ALIGNMENT HEALTHCARE | 20,260 | -10,12 % | Alignment Healthcare forecasts $138M-$163M adjusted EBITDA for 2026 as membership outlook rises to 294,000-299,000 | ||
| HEARTFLOW | 28,670 | -3,66 % | Heartflow, Inc.: Heartflow Files Patent Infringement Lawsuit Against Cleerly | MOUNTAIN VIEW, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced that it has filed... ► Artikel lesen | |
| LIFESTANCE HEALTH GROUP | 7,530 | -0,53 % | S&P Dow Jones Indices: LifeStance Health Group Set to Join S&P SmallCap 600 | NEW YORK, April 27, 2026 /PRNewswire/ -- LifeStance Health Group Inc. (NASD: LFST) will replace Golden Entertainment Inc (NASD: GDEN) in the S&P SmallCap 600 effective... ► Artikel lesen | |
| PROGYNY | 18,610 | +0,16 % | Progyny, Inc. Announces Third Quarter 2025 Results | Reports Revenue of $313.3 Million, Reflecting 9.3% GrowthRaises Full Year Guidance to Reflect Continued Strength in Member EngagementSelling Season Yields Over 80 New Clients, 900,000 New Lives, and... ► Artikel lesen | |
| PRIVIA HEALTH GROUP | 24,850 | 0,00 % | Privia Health Group, Inc.: Privia Health Reports Fourth Quarter and Full-Year 2025 Financial Results | All 2025 Operating and Financial Metrics At or Above High End of Guidance RangesFull-year 2025 Net Income +59.3% from 2024Full-year 2025 Adjusted EBITDA of $125.5 Million, +38.8% from 2024Full-year... ► Artikel lesen | |
| BILLIONTOONE | 77,70 | +3,53 % | BillionToOne, Inc.: BillionToOne Reports Fourth Quarter and Full Year 2025 Results and Raises 2026 Revenue Guidance | MENLO PARK, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that... ► Artikel lesen | |
| PROCEPT BIOROBOTICS | 24,630 | +2,41 % | PROCEPT BioRobotics Reports First Quarter 2026 Financial Results | SAN JOSE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative... ► Artikel lesen | |
| GENEDX | 65,36 | +3,93 % | Will Robust Exome and Genome Revenues Lift GeneDx's Q1 Earnings? | ||
| ONCOLOGY INSTITUTE | 4,050 | +4,92 % | Here's What Powered The Oncology Institute's (TOI) Gains | ||
| AIRSCULPT TECHNOLOGIES | 3,320 | +23,88 % | Airsculpt Technologies, Inc.: AirSculpt Technologies Reports Fourth Quarter and Full Year Fiscal 2025 Results | MIAMI BEACH, Fla., April 02, 2026 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. (NASDAQ:AIRS)("AirSculpt" or the "Company"), a national provider of premium body contouring procedures, today announced... ► Artikel lesen | |
| BUTTERFLY NETWORK | 5,395 | +13,22 % | Butterfly Network shares fall despite Q1 earnings and revenue beat | ||
| LIFEMD | 5,000 | +6,84 % | LifeMD, Inc.: LifeMD to Report First Quarter 2026 Financial Results on May 6 | ||
| ALPHA TAU MEDICAL | 8,540 | +2,40 % | Alpha Tau: Abstract zu Bauchspeicheldrüsenkrebs für ASCO-Jahrestagung angenommen | ||
| ADAPTHEALTH | 13,170 | +0,46 % | AdaptHealth refinances $1.1B senior secured credit facility |
Das Unternehmen NEUROPACE INC kann der Branche Gesundheitswesen zugeordnet werden. Die relative Kursveränderung beträgt aktuell +1,13 % bei einem Aktienkurs von 17,060 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NEUROPACE INC finden Sie auf Wallstreet Online.